Primobolan does not aromatize to estrogen, eliminating water retention and gynecomastia concerns
Whether you're #TeamOzempic, #TeamWegovy, or #TeamMounjaro, one thing is for sure - the world of weight loss has never been more captivating!
Annals of Internal Medicine, 117(3), 234-242
Physique: The body composition changes are now evident to other people
Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management